Public Employees Retirement System of Ohio Buys New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Public Employees Retirement System of Ohio purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the third quarter, Holdings Channel.com reports. The fund purchased 22,356 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,491,000.

Several other large investors have also bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 121 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Jazz Pharmaceuticals by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after purchasing an additional 130 shares during the period. Itau Unibanco Holding S.A. boosted its holdings in shares of Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares during the last quarter. Finally, Waterfront Wealth Inc. grew its position in Jazz Pharmaceuticals by 2.5% during the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock valued at $1,004,000 after buying an additional 230 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ:JAZZ opened at $122.49 on Wednesday. The firm has a market capitalization of $7.41 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The firm has a fifty day moving average of $117.72 and a 200 day moving average of $112.36.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,753 shares of company stock worth $816,289. 4.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have issued reports on JAZZ shares. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.